Prevention of shivering during therapeutic temperature modulation

The Columbia anti-shivering protocol

H. Alex Choi, Sang Bae Ko, Mary Presciutti, Luis Fernandez, Amanda M. Carpenter, Christine Lesch, Emily Gilmore, Rishi Malhotra, Stephan A. Mayer, Kiwon Lee, Jan Claassen, J. Michael Schmidt, Neeraj Badjatia

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Background: As the practice of aggressive temperature control has become more commonplace, new clinical problems are arising, of which shivering is the most common. Treatment for shivering while avoiding the negative consequences of many anti-shivering therapies is often difficult. We have developed a stepwise protocol that emphasizes use of the least sedating regimen to achieve adequate shiver control. Methods: All patients treated with temperature modulating devices in the neurological intensive care unit were prospectively entered into a database. Baseline demographic information, daily temperature goals, best daily GCS, and type and cumulative dose of anti-shivering agents were recorded. Results: We collected 213 patients who underwent 1388 patient days of temperature modulation. Eighty-nine patients underwent hypothermia and 124 patients underwent induced normothermia. In 18% of patients and 33% of the total patient days only none-sedating baseline interventions were needed. The first agent used was most commonly dexmeditomidine at 50% of the time, followed by an opiate and increased doses of propofol. Younger patients, men, and decreased BSA were factors associated with increased number of anti-shivering interventions. Conclusions: A significant proportion of patients undergoing temperature modulation can be effectively treated for shivering without over-sedation and paralysis. Patients at higher risk for needing more interventions are younger men with decreased BSA.

Original languageEnglish (US)
Pages (from-to)389-394
Number of pages6
JournalNeurocritical Care
Volume14
Issue number3
DOIs
StatePublished - Jun 2011
Externally publishedYes

Fingerprint

Shivering
Temperature
Therapeutics
Opiate Alkaloids
Propofol
Hypothermia
Paralysis
Intensive Care Units
Demography
Databases

Keywords

  • Dexmedetomidine
  • Hypothermia
  • Meperidine
  • Normothermia
  • Shivering

ASJC Scopus subject areas

  • Clinical Neurology
  • Critical Care and Intensive Care Medicine

Cite this

Choi, H. A., Ko, S. B., Presciutti, M., Fernandez, L., Carpenter, A. M., Lesch, C., ... Badjatia, N. (2011). Prevention of shivering during therapeutic temperature modulation: The Columbia anti-shivering protocol. Neurocritical Care, 14(3), 389-394. https://doi.org/10.1007/s12028-010-9474-7

Prevention of shivering during therapeutic temperature modulation : The Columbia anti-shivering protocol. / Choi, H. Alex; Ko, Sang Bae; Presciutti, Mary; Fernandez, Luis; Carpenter, Amanda M.; Lesch, Christine; Gilmore, Emily; Malhotra, Rishi; Mayer, Stephan A.; Lee, Kiwon; Claassen, Jan; Schmidt, J. Michael; Badjatia, Neeraj.

In: Neurocritical Care, Vol. 14, No. 3, 06.2011, p. 389-394.

Research output: Contribution to journalArticle

Choi, HA, Ko, SB, Presciutti, M, Fernandez, L, Carpenter, AM, Lesch, C, Gilmore, E, Malhotra, R, Mayer, SA, Lee, K, Claassen, J, Schmidt, JM & Badjatia, N 2011, 'Prevention of shivering during therapeutic temperature modulation: The Columbia anti-shivering protocol', Neurocritical Care, vol. 14, no. 3, pp. 389-394. https://doi.org/10.1007/s12028-010-9474-7
Choi, H. Alex ; Ko, Sang Bae ; Presciutti, Mary ; Fernandez, Luis ; Carpenter, Amanda M. ; Lesch, Christine ; Gilmore, Emily ; Malhotra, Rishi ; Mayer, Stephan A. ; Lee, Kiwon ; Claassen, Jan ; Schmidt, J. Michael ; Badjatia, Neeraj. / Prevention of shivering during therapeutic temperature modulation : The Columbia anti-shivering protocol. In: Neurocritical Care. 2011 ; Vol. 14, No. 3. pp. 389-394.
@article{1b5106add89847f7b295f7dfc344f2ce,
title = "Prevention of shivering during therapeutic temperature modulation: The Columbia anti-shivering protocol",
abstract = "Background: As the practice of aggressive temperature control has become more commonplace, new clinical problems are arising, of which shivering is the most common. Treatment for shivering while avoiding the negative consequences of many anti-shivering therapies is often difficult. We have developed a stepwise protocol that emphasizes use of the least sedating regimen to achieve adequate shiver control. Methods: All patients treated with temperature modulating devices in the neurological intensive care unit were prospectively entered into a database. Baseline demographic information, daily temperature goals, best daily GCS, and type and cumulative dose of anti-shivering agents were recorded. Results: We collected 213 patients who underwent 1388 patient days of temperature modulation. Eighty-nine patients underwent hypothermia and 124 patients underwent induced normothermia. In 18{\%} of patients and 33{\%} of the total patient days only none-sedating baseline interventions were needed. The first agent used was most commonly dexmeditomidine at 50{\%} of the time, followed by an opiate and increased doses of propofol. Younger patients, men, and decreased BSA were factors associated with increased number of anti-shivering interventions. Conclusions: A significant proportion of patients undergoing temperature modulation can be effectively treated for shivering without over-sedation and paralysis. Patients at higher risk for needing more interventions are younger men with decreased BSA.",
keywords = "Dexmedetomidine, Hypothermia, Meperidine, Normothermia, Shivering",
author = "Choi, {H. Alex} and Ko, {Sang Bae} and Mary Presciutti and Luis Fernandez and Carpenter, {Amanda M.} and Christine Lesch and Emily Gilmore and Rishi Malhotra and Mayer, {Stephan A.} and Kiwon Lee and Jan Claassen and Schmidt, {J. Michael} and Neeraj Badjatia",
year = "2011",
month = "6",
doi = "10.1007/s12028-010-9474-7",
language = "English (US)",
volume = "14",
pages = "389--394",
journal = "Neurocritical Care",
issn = "1541-6933",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Prevention of shivering during therapeutic temperature modulation

T2 - The Columbia anti-shivering protocol

AU - Choi, H. Alex

AU - Ko, Sang Bae

AU - Presciutti, Mary

AU - Fernandez, Luis

AU - Carpenter, Amanda M.

AU - Lesch, Christine

AU - Gilmore, Emily

AU - Malhotra, Rishi

AU - Mayer, Stephan A.

AU - Lee, Kiwon

AU - Claassen, Jan

AU - Schmidt, J. Michael

AU - Badjatia, Neeraj

PY - 2011/6

Y1 - 2011/6

N2 - Background: As the practice of aggressive temperature control has become more commonplace, new clinical problems are arising, of which shivering is the most common. Treatment for shivering while avoiding the negative consequences of many anti-shivering therapies is often difficult. We have developed a stepwise protocol that emphasizes use of the least sedating regimen to achieve adequate shiver control. Methods: All patients treated with temperature modulating devices in the neurological intensive care unit were prospectively entered into a database. Baseline demographic information, daily temperature goals, best daily GCS, and type and cumulative dose of anti-shivering agents were recorded. Results: We collected 213 patients who underwent 1388 patient days of temperature modulation. Eighty-nine patients underwent hypothermia and 124 patients underwent induced normothermia. In 18% of patients and 33% of the total patient days only none-sedating baseline interventions were needed. The first agent used was most commonly dexmeditomidine at 50% of the time, followed by an opiate and increased doses of propofol. Younger patients, men, and decreased BSA were factors associated with increased number of anti-shivering interventions. Conclusions: A significant proportion of patients undergoing temperature modulation can be effectively treated for shivering without over-sedation and paralysis. Patients at higher risk for needing more interventions are younger men with decreased BSA.

AB - Background: As the practice of aggressive temperature control has become more commonplace, new clinical problems are arising, of which shivering is the most common. Treatment for shivering while avoiding the negative consequences of many anti-shivering therapies is often difficult. We have developed a stepwise protocol that emphasizes use of the least sedating regimen to achieve adequate shiver control. Methods: All patients treated with temperature modulating devices in the neurological intensive care unit were prospectively entered into a database. Baseline demographic information, daily temperature goals, best daily GCS, and type and cumulative dose of anti-shivering agents were recorded. Results: We collected 213 patients who underwent 1388 patient days of temperature modulation. Eighty-nine patients underwent hypothermia and 124 patients underwent induced normothermia. In 18% of patients and 33% of the total patient days only none-sedating baseline interventions were needed. The first agent used was most commonly dexmeditomidine at 50% of the time, followed by an opiate and increased doses of propofol. Younger patients, men, and decreased BSA were factors associated with increased number of anti-shivering interventions. Conclusions: A significant proportion of patients undergoing temperature modulation can be effectively treated for shivering without over-sedation and paralysis. Patients at higher risk for needing more interventions are younger men with decreased BSA.

KW - Dexmedetomidine

KW - Hypothermia

KW - Meperidine

KW - Normothermia

KW - Shivering

UR - http://www.scopus.com/inward/record.url?scp=79955797360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955797360&partnerID=8YFLogxK

U2 - 10.1007/s12028-010-9474-7

DO - 10.1007/s12028-010-9474-7

M3 - Article

VL - 14

SP - 389

EP - 394

JO - Neurocritical Care

JF - Neurocritical Care

SN - 1541-6933

IS - 3

ER -